WHAT’S NEW IN SOFT TISSUE AND BONE PATHOLOGY 2022—UPDATES FROM THE WHO CLASSIFICATION 5TH EDITION

Erica Y. Kao¹, Jose G. Mantilla²

¹Department of Pathology, Brooke Army Medical Center, San Antonio, TX, USA
²Department of Pathology, University of Washington, Seattle, WA, USA

Corresponding Author: Erica Y. Kao, MD
Department of Pathology, Brooke Army Medical Center, San Antonio, Texas, USA
E-mail: erica.kao.mil@health.mil

ORCID
Erica Y. Kao
https://orcid.org/0000-0001-6005-3559
Jose G. Mantilla
https://orcid.org/0000-0003-4752-6459

Abstract
The 2020 release of the WHO Classification of Soft Tissue and Bone Tumors, 5th edition, contains several changes driven by new knowledge in the field. These include reclassification of some entities, refinement of risk classification systems, and the inclusion of novel disease processes, many of which are driven by recurrent gene fusions. The most notable changes are described here.

SELECT NEW ENTITIES

Lipomatous tumors
- Atypical spindle cell/pleomorphic lipomatous tumor
- Composed of variable proportions of atypical spindle cells, adipocytes, univacuolated or multivacuolated lipoblasts, pleomorphic to multinucleated cells, and myxoid to collagenous stroma.
- Lack of MDM2 or CDK4 amplification.
- Rb expression is generally lost.
- Low rate of local recurrence (10%–15%); no known risk of dedifferentiation.
- Myxoid pleomorphic liposarcoma
- Occurs predominantly in children and young adults with a predilection for the mediastinum.
- Admixture of areas resembling myxoid liposarcoma with more cellular areas containing overt nuclear pleomorphism, which resembles pleomorphic liposarcoma.
- Lacks recurrent chromosomal changes, namely MDM2 amplification and DDIT3 gene fusion.
- Clinical behavior akin to pleomorphic liposarcoma.

Smooth muscle tumors
- Inflammatory leiomyosarcoma
- Rare, and thought to be relatively indolent compared to conventional leiomyosarcoma.
- Typically arise in the deep extremities.
- Variably atypical eosinophilic spindle cells in fascicles, with mitotic activity and prominent, usually diffuse, mixed (predominantly mononuclear) inflammatory infiltrate.
- Near-haploid karyotype.
- EBV-associated smooth muscle tumor
- Associated with EBV infection, usually in the setting of immunosuppression.
- Can arise in any anatomic location, most often in visceral sites and CNS.
- Prognosis depends on the patient’s immune condition. Most tumors do not metastasize.
- Cytologic atypia is highly variable. In half of cases, a second population of more primitive appearing round cells are seen. T-cell inflammatory infiltrates are common.
- Invariably positive expression of EBER.

Fibroblastic/myofibroblastic tumors
- EWSR1::SMAD4 positive fibroblastic tumor
- Small dermal and subcutaneous acral nodule, with indolent biological behavior.
- Histologic zonation with acellular hyalinized center and peripheral fascicular monomorphic spindle cell growth.
- Diffuse ERG nuclear expression in the absence of CD34 and SMA expression.
- EWSR1::SMAD4 fusion.
- Angiofibroma of soft tissue
- Benign neoplasm with rare local recurrence.
- Uniformly bland short spindle cells in variably myxoid to collagenous stroma, with prominent vascular network of small thin-walled branching blood vessels (Fig. 1).
- NCOA2 gene rearrangements in up to 80%.
- Superficial CD34-positive fibroblastic tumor
- Rare, slow-growing, indolent neoplasm.
- Superficial location, typically in the lower extremities.
- Large eosinophilic cells with granular to glassy cytoplasm; marked pleomorphism with low mitotic count (Fig. 2).
- CD34 and frequent keratin expression.

Fig. 1. Angiofibroma of soft tissue.
Fig. 2. Superficial CD34-positive fibroblastic tumor.
Vascular tumors

- Anastomosing hemangioma
  - Benign vascular neoplasm. Often arises in viscera and can be multifocal.
  - Thin-walled anastomosing vessels lined by hobnail endothelial cells. Vascular thrombi are typical. Loosely lobulated architecture with focal infiltration into adjoining tissue. May be associated with a medium-caliber vessel.
  - Activating mutations in GNAQ or GNA14.
- Epithelioid hemangioendothelioma with YAP1::TFE3 gene fusion
  - Considered to have a generally more aggressive behavior.
  - Tends to have more solid growth and be vasoformative, compared to cases harboring WWTR1::CAMTA1 fusion.

Tumors of uncertain differentiation

- Kinase gene-rearranged spindle cell neoplasms
  - Outside of infantile fibrosarcoma, this represents an emerging group of tumors with a wide morphologic spectrum.
  - Most tumors have co-expression of S100 and CD34 in the absence of SOX10.
  - They can resemble lipofibromatosis or can be composed of monomorphic spindle cells with prominent collagen deposition and hyalinization; amianthoid-like fibers and infiltrative growth may also be present.
  - Harbor gene fusions involving kinase genes, such as NTRK, ALK, RAF1 and BRAF.

Undifferentiated round cell sarcomas

Due to the recent expansion in molecular studies, multiple recurrent gene fusions have been described in previously unclassified round cell sarcomas. These lesions have been shown to have particular clinical and morphologic features. These include:

- Round cell sarcoma with EWSR1::non-ETS fusions
  - Round and spindle cell sarcomas with fusions in EWSR1 or FUS with partners unrelated to the ETS gene family, most commonly NFATC2 or PATZ1 genes.
  - Tumors with EWSR1::NFATC2 consist of round or spindled cells arranged in cords, nests and trabeculae in a myxohyaline background (Fig. 3). They may have focal dot-like keratin and CD138 expression. They may morphologically mimic myoepithelial neoplasms or ossifying fibromyxoid tumor, among others.
  - Sarcomas with EWSR1::PATZ1 fusion have a broad morphologic spectrum. They may have round to spindle cells within a fibrous stroma. Co-expression of myogenic and nerve sheath markers has been described.
- CIC rearranged sarcoma
  - Round cell sarcoma characterized by CIC gene fusions, most commonly CIC::DUX4. Other fusion partners include FOXO4, LEUTX, NUTM1 and NUTM2A.
  - Composed of sheets of large round cells with mild nuclear pleomorphism, lightly eosinophilic cytoplasm, geographic necrosis and brisk mitotic activity (Fig. 4).

Fig. 4. CIC-rearranged sarcoma.

- Immunohistochemically, they show variable CD99 expression, nuclear WT1 and DUX4 reactivity.
- Response to chemotherapy is poor compared to Ewing sarcoma and BCROR fusion sarcomas.
- Sarcoma with BCROR alterations
  - Primary round cell sarcoma with BCROR gene fusions, most commonly BCROR::CCNB3, followed by BCROR internal tandem duplication.
  - Composed of primitive round to spindled cells in nests, sheets or fascicles in variably myxoid stroma, which may morphologically resemble synovial sarcoma. Their clinical response to chemotherapy is favorable when compared to Ewing sarcoma and CIC-fusion sarcomas.
  - Sarcomas with BCROR fusion are slightly more common in bone and tend to arise in patients younger than 20 years. On the other hand, sarcomas with BCROR internal tandem duplication tend to arise in the soft tissues of the trunk, retroperitoneum, and head and neck. These usually occur within the first year of life or may present at birth.

CHANGES IN NOMENCLATURE

- Mammary-type myofibroblastoma has been renamed as myofibroblastoma.
- Melanotic schwannoma has been renamed to malignant melanotic nerve sheath tumor. This change better reflects its aggressive clinical behavior.

OTHER CHANGES

- Solitary fibrous tumor
  - Risk stratification based on age, tumor size, mitotic activity, and necrosis is recommended (Mod Pathol 2017;30:1433-1442).
- Spindle cell/sclerosing rhabdomyosarcoma
  - Subclassification depends on the presence of genetic alterations associated with prognosis.
  - Tumors with VGLL2, NCOA2 and CITED2 gene rearrangements typically arise in infants and have favorable prognosis.
  - Tumors with MYOD1 mutations usually arise in adolescents and adults, and have unfavorable prognosis.
  - Tumors with TFCP2/NCOA2 gene rearrangements can be intraosseous.

Meet the Author

Dr. Kao has been an author for PathologyOutlines since 2020. She is currently a staff pathologist at Brooke Army Medical Center in San Antonio, TX in where she practices Bone and Soft Tissue pathology. She is an Assistant Professor for the Uniformed Services University of the Health Sciences. She obtained her M.D. at the Uniformed Services University of the Health Sciences in Bethesda, MD, completed her residency in AP/CP Pathology at Brooke Army Medical Center, and fellowship in Bone and Soft Tissue Pathology at the University of Washington.

Dr. Mantilla has been an author for PathologyOutlines since 2019 and part of the PathologyOutlines editorial board since December 2020. He is an Assistant Professor of Laboratory Medicine and Pathology and Program Director of the Surgical Pathology fellowship at the University of Washington in Seattle. He obtained his M.D. at the Pontificia Universidad Javeriana (Bogotá, Colombia), followed by a residency in Anatomic and Clinical Pathology at Montefiore Medical Center in New York and fellowships in Surgical Pathology and Bone and Soft Tissue Pathology at the University of Washington.